Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Novel Ran-RCC1 Inhibitory Peptide-Loaded Nanoparticles Have Anti-Cancer Efficacy In Vitro and In Vivo.

Haggag YA, Matchett KB, Falconer RA, Isreb M, Jones J, Faheem A, McCarron P, El-Tanani M.

Cancers (Basel). 2019 Feb 14;11(2). pii: E222. doi: 10.3390/cancers11020222.

2.

Anti-Invasive and Anti-Proliferative Effects of shRNA-Loaded Poly(Lactide-Co-Glycolide) Nanoparticles Following RAN Silencing in MDA-MB231 Breast Cancer Cells.

Sharma A, McCarron P, Matchett K, Hawthorne S, El-Tanani M.

Pharm Res. 2018 Dec 17;36(2):26. doi: 10.1007/s11095-018-2555-6.

3.

The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer.

Dakir EH, Pickard A, Srivastava K, McCrudden CM, Gross SR, Lloyd S, Zhang SD, Margariti A, Morgan R, Rudland PS, El-Tanani M.

Oncotarget. 2018 Oct 9;9(79):34889-34910. doi: 10.18632/oncotarget.26175. eCollection 2018 Oct 9.

4.

Enhanced cutaneous wound healing in rats following topical delivery of insulin-loaded nanoparticles embedded in poly(vinyl alcohol)-borate hydrogels.

Abdelkader DH, Tambuwala MM, Mitchell CA, Osman MA, El-Gizawy SA, Faheem AM, El-Tanani M, McCarron PA.

Drug Deliv Transl Res. 2018 Oct;8(5):1053-1065. doi: 10.1007/s13346-018-0554-0.

5.

Clinical and in vitro analysis of Osteopontin as a prognostic indicator and unveil its potential downstream targets in bladder cancer.

Wong JPC, Wei R, Lyu P, Tong OLH, Zhang SD, Wen Q, Yuen HF, El-Tanani M, Kwok HF.

Int J Biol Sci. 2017 Nov 1;13(11):1373-1386. doi: 10.7150/ijbs.21457. eCollection 2017.

6.

Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells.

Alharbi RA, Pandha HS, Simpson GR, Pettengell R, Poterlowicz K, Thompson A, Harrington K, El-Tanani M, Morgan R.

Oncotarget. 2017 Aug 7;8(52):89566-89579. doi: 10.18632/oncotarget.20023. eCollection 2017 Oct 27.

7.

Targeting HOX/PBX dimers in cancer.

Morgan R, El-Tanani M, Hunter KD, Harrington KJ, Pandha HS.

Oncotarget. 2017 May 9;8(19):32322-32331. doi: 10.18632/oncotarget.15971. Review.

8.

Erythropoietin drives breast cancer progression by activation of its receptor EPOR.

Chan KK, Matchett KB, Coulter JA, Yuen HF, McCrudden CM, Zhang SD, Irwin GW, Davidson MA, Rülicke T, Schober S, Hengst L, Jaekel H, Platt-Higgins A, Rudland PS, Mills KI, Maxwell P, El-Tanani M, Lappin TR.

Oncotarget. 2017 Jun 13;8(24):38251-38263. doi: 10.18632/oncotarget.16368.

9.

Nano-encapsulation of a novel anti-Ran-GTPase peptide for blockade of regulator of chromosome condensation 1 (RCC1) function in MDA-MB-231 breast cancer cells.

Haggag YA, Matchett KB, Dakir el-H, Buchanan P, Osman MA, Elgizawy SA, El-Tanani M, Faheem AM, McCarron PA.

Int J Pharm. 2017 Apr 15;521(1-2):40-53. doi: 10.1016/j.ijpharm.2017.02.006. Epub 2017 Feb 2.

PMID:
28163220
10.

Ran GTPase promotes cancer progression via Met recepto-rmediated downstream signaling.

Yuen HF, Chan KK, Platt-Higgins A, Dakir el-H, Matchett KB, Haggag YA, Jithesh PV, Habib T, Faheem A, Dean FA, Morgan R, Rudland PS, El-Tanani M.

Oncotarget. 2016 Nov 15;7(46):75854-75864. doi: 10.18632/oncotarget.12420.

11.

Mechanisms of Nuclear Export in Cancer and Resistance to Chemotherapy.

El-Tanani M, Dakir el-H, Raynor B, Morgan R.

Cancers (Basel). 2016 Mar 14;8(3). pii: E35. doi: 10.3390/cancers8030035. Review.

12.

HOX Genes as Potential Markers of Circulating Tumour Cells.

Morgan R, El-Tanani M.

Curr Mol Med. 2016;16(4):322-7. Review.

PMID:
26980702
13.

Preparation and in vivo evaluation of insulin-loaded biodegradable nanoparticles prepared from diblock copolymers of PLGA and PEG.

Haggag Y, Abdel-Wahab Y, Ojo O, Osman M, El-Gizawy S, El-Tanani M, Faheem A, McCarron P.

Int J Pharm. 2016 Feb 29;499(1-2):236-246. doi: 10.1016/j.ijpharm.2015.12.063. Epub 2015 Dec 30.

PMID:
26746800
14.

Resistance to HSP90 inhibition involving loss of MCL1 addiction.

Busacca S, Law EW, Powley IR, Proia DA, Sequeira M, Le Quesne J, Klabatsa A, Edwards JM, Matchett KB, Luo JL, Pringle JH, El-Tanani M, MacFarlane M, Fennell DA.

Oncogene. 2016 Mar 24;35(12):1483-92. doi: 10.1038/onc.2015.213. Epub 2015 Jun 22.

15.

Protein deregulation associated with breast cancer metastasis.

Chan KK, Matchett KB, McEnhill PM, Dakir el H, McMullin MF, El-Tanani Y, Patterson L, Faheem A, Rudland PS, McCarron PA, El-Tanani M.

Cytokine Growth Factor Rev. 2015 Aug;26(4):415-23. doi: 10.1016/j.cytogfr.2015.05.002. Epub 2015 May 31. Review.

PMID:
26088937
16.

Novel antibodies directed against the human erythropoietin receptor: creating a basis for clinical implementation.

Maxwell P, Melendez-Rodríguez F, Matchett KB, Aragones J, Ben-Califa N, Jaekel H, Hengst L, Lindner H, Bernardini A, Brockmeier U, Fandrey J, Grunert F, Oster HS, Mittelman M, El-Tanani M, Thiersch M, Schneider Gasser EM, Gassmann M, Dangoor D, Cuthbert RJ, Irvine A, Jordan A, Lappin T, Thompson J, Neumann D.

Br J Haematol. 2015 Feb;168(3):429-42. doi: 10.1111/bjh.13133. Epub 2014 Oct 4.

PMID:
25283956
17.

Ran GTPase in nuclear envelope formation and cancer metastasis.

Matchett KB, McFarlane S, Hamilton SE, Eltuhamy YS, Davidson MA, Murray JT, Faheem AM, El-Tanani M.

Adv Exp Med Biol. 2014;773:323-51. doi: 10.1007/978-1-4899-8032-8_15. Review.

PMID:
24563355
18.

BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.

Busacca S, Chacko AD, Klabatsa A, Arthur K, Sheaff M, Barbone D, Mutti L, Gunasekharan VK, Gorski JJ, El-Tanani M, Broaddus VC, Gaudino G, Fennell DA.

PLoS One. 2013 Jun 7;8(6):e65489. doi: 10.1371/journal.pone.0065489. Print 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/90879c69-ebc5-40b2-9926-4a00e4f9e055. Barbone, Dario [added]; Mutti, Luciano [added].

19.

RanGTPase: a candidate for Myc-mediated cancer progression.

Yuen HF, Gunasekharan VK, Chan KK, Zhang SD, Platt-Higgins A, Gately K, O'Byrne K, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

J Natl Cancer Inst. 2013 Apr 3;105(7):475-88. doi: 10.1093/jnci/djt028. Epub 2013 Mar 6.

PMID:
23468463
20.

Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.

Yuen HF, Abramczyk O, Montgomery G, Chan KK, Huang YH, Sasazuki T, Shirasawa S, Gopesh S, Chan KW, Fennell D, Janne P, El-Tanani M, Murray JT.

Biosci Rep. 2012 Aug;32(4):413-22. doi: 10.1042/BSR20120050.

21.

Combinatorial use of bone morphogenetic protein 6, noggin and SOST significantly predicts cancer progression.

Yuen HF, McCrudden CM, Grills C, Zhang SD, Huang YH, Chan KK, Chan YP, Wong ML, Law S, Srivastava G, Fennell DA, Dickson G, El-Tanani M, Chan KW.

Cancer Sci. 2012 Jun;103(6):1145-54. doi: 10.1111/j.1349-7006.2012.02252.x. Epub 2012 Apr 3.

22.

Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.

Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

Clin Cancer Res. 2012 Jan 15;18(2):380-91. doi: 10.1158/1078-0432.CCR-11-2035. Epub 2011 Nov 16.

23.

Regarding "Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients".

Yuen HF, Zhang SD, Wong AS, McCrudden CM, Huang YH, Chan KY, El-Tanani M, Khoo US.

Breast Cancer Res Treat. 2012 Jan;131(1):351-2. doi: 10.1007/s10549-011-1831-5. Epub 2011 Oct 26. No abstract available.

PMID:
22037786
24.

RAN GTPase as a target for cancer therapy: Ran binding proteins.

Doherty KJ, McKay C, Chan KK, El-Tanani MK.

Curr Mol Med. 2011 Nov;11(8):686-95. Review.

PMID:
21902650
25.

Wnt-β-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer.

Ravindranath A, Yuen HF, Chan KK, Grills C, Fennell DA, Lappin TR, El-Tanani M.

Br J Cancer. 2011 Aug 9;105(4):542-51. doi: 10.1038/bjc.2011.269. Epub 2011 Jul 19.

26.

The role of Pea3 group transcription factors in esophageal squamous cell carcinoma.

Yuen HF, McCrudden CM, Chan KK, Chan YP, Wong ML, Chan KY, Khoo US, Law S, Srivastava G, Lappin TR, Chan KW, El-Tanani M.

Am J Pathol. 2011 Aug;179(2):992-1003. doi: 10.1016/j.ajpath.2011.04.004. Epub 2011 May 31.

27.

Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snail-induced epithelial-mesenchymal transition.

Yuen HF, Chan YK, Grills C, McCrudden CM, Gunasekharan V, Shi Z, Wong AS, Lappin TR, Chan KW, Fennell DA, Khoo US, Johnston PG, El-Tanani M.

J Pathol. 2011 May;224(1):78-89. doi: 10.1002/path.2859. Epub 2011 Mar 14.

PMID:
21404275
28.

Expression of osteopontin coregulators in primary colorectal cancer and associated liver metastases.

Mole DJ, O'Neill C, Hamilton P, Olabi B, Robinson V, Williams L, Diamond T, El-Tanani M, Campbell FC.

Br J Cancer. 2011 Mar 15;104(6):1007-12. doi: 10.1038/bjc.2011.33. Epub 2011 Feb 22.

29.

Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells.

El-Tanani MK, Yuen HF, Shi Z, Platt-Higgins A, Buckley NE, Mullan PB, Harkin DP, Johnston PG, Rudland PS.

Cancer Sci. 2010 Jun;101(6):1354-60. doi: 10.1111/j.1349-7006.2010.01561.x. Epub 2010 Mar 10.

30.

Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.

Shi Z, Hodges VM, Dunlop EA, Percy MJ, Maxwell AP, El-Tanani M, Lappin TR.

Mol Cancer Res. 2010 Apr;8(4):615-26. doi: 10.1158/1541-7786.MCR-09-0264. Epub 2010 Mar 30.

31.

Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1.

Yuen HF, Chiu YT, Chan KK, Chan YP, Chua CW, McCrudden CM, Tang KH, El-Tanani M, Wong YC, Wang X, Chan KW.

Br J Cancer. 2010 Jan 19;102(2):332-41. doi: 10.1038/sj.bjc.6605480. Epub 2009 Dec 15.

32.

Interferon-induced transmembrane 3 binds osteopontin in vitro: expressed in vivo IFITM3 reduced OPN expression.

El-Tanani MK, Jin D, Campbell FC, Johnston PG.

Oncogene. 2010 Feb 4;29(5):752-62. doi: 10.1038/onc.2009.379. Epub 2009 Nov 9.

PMID:
19901966
33.

The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control.

Campbell FC, Xu H, El-Tanani M, Crowe P, Bingham V.

Biochem Pharmacol. 2010 Jan 1;79(1):1-9. doi: 10.1016/j.bcp.2009.09.005. Epub 2009 Sep 6. Review.

34.

Identification of genes differentially expressed between benign and osteopontin transformed rat mammary epithelial cells.

Kurisetty VV, Johnston PG, Rudland PS, El-Tanani MK.

BMC Res Notes. 2009 Feb 3;2:15. doi: 10.1186/1756-0500-2-15.

35.

Vitamin D receptor modulates the neoplastic phenotype through antagonistic growth regulatory signals.

Xu H, McCann M, Zhang Z, Posner GH, Bingham V, El-Tanani M, Campbell FC.

Mol Carcinog. 2009 Aug;48(8):758-72. doi: 10.1002/mc.20520.

PMID:
19184984
36.

Synthesis of A83586C analogs with potent anticancer and beta-catenin/ TCF4/osteopontin inhibitory effects and insights into how A83586C modulates E2Fs and pRb.

Hale KJ, Manaviazar S, Lazarides L, George J, Walters MA, Cai J, Delisser VM, Bhatia GS, Peak SA, Dalby SM, Lefranc A, Chen YN, Wood AW, Crowe P, Erwin P, El-Tanani M.

Org Lett. 2009 Feb 5;11(3):737-40. doi: 10.1021/ol802818f.

PMID:
19175352
37.

Osteopontin: a new role for a familiar actor.

Johnston NI, El-Tanani MK.

Breast Cancer Res. 2008;10(6):306. doi: 10.1186/bcr2199. Epub 2008 Dec 1.

38.

DJ-1 could predict worse prognosis in esophageal squamous cell carcinoma.

Yuen HF, Chan YP, Law S, Srivastava G, El-Tanani M, Mak TW, Chan KW.

Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3593-602. doi: 10.1158/1055-9965.EPI-08-0214.

39.

RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin.

Kurisetty VV, Johnston PG, Johnston N, Erwin P, Crowe P, Fernig DG, Campbell FC, Anderson IP, Rudland PS, El-Tanani MK.

Oncogene. 2008 Dec 4;27(57):7139-49. doi: 10.1038/onc.2008.325. Epub 2008 Sep 15.

PMID:
18794800
40.

Osteopontin as a target for cancer therapy.

Johnston NI, Gunasekharan VK, Ravindranath A, O'Connell C, Johnston PG, El-Tanani MK.

Front Biosci. 2008 May 1;13:4361-72. Review.

PMID:
18508515
41.

Role of osteopontin in cellular signaling and metastatic phenotype.

El-Tanani MK.

Front Biosci. 2008 May 1;13:4276-84. Review.

PMID:
18508510
42.

Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation.

Mason CK, McFarlane S, Johnston PG, Crowe P, Erwin PJ, Domostoj MM, Campbell FC, Manaviazar S, Hale KJ, El-Tanani M.

Mol Cancer Ther. 2008 Mar;7(3):548-58. doi: 10.1158/1535-7163.MCT-07-2251.

43.

The role of LEF/TCF factors in neoplastic transformation.

Ravindranath A, O'Connell A, Johnston PG, El-Tanani MK.

Curr Mol Med. 2008 Feb;8(1):38-50. Review.

PMID:
18289012
44.
45.

The regulation and role of osteopontin in malignant transformation and cancer.

El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS.

Cytokine Growth Factor Rev. 2006 Dec;17(6):463-74. Epub 2006 Nov 17. Review.

PMID:
17113338
46.

Identification of apolipoprotein D as a novel inhibitor of osteopontin-induced neoplastic transformation.

Jin D, El-Tanani M, Campbell FC.

Int J Oncol. 2006 Dec;29(6):1591-9.

PMID:
17089001
47.

BRCA1 suppresses osteopontin-mediated breast cancer.

El-Tanani MK, Campbell FC, Crowe P, Erwin P, Harkin DP, Pharoah P, Ponder B, Rudland PS.

J Biol Chem. 2006 Sep 8;281(36):26587-601. Epub 2006 Jun 28.

48.

Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription.

El-Tanani M, Platt-Higgins A, Rudland PS, Campbell FC.

J Biol Chem. 2004 May 14;279(20):20794-806. Epub 2004 Feb 27.

49.

Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.

Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR.

Cancer Res. 2002 Jun 15;62(12):3417-27.

50.

Differential modulation of transcriptional activity of estrogen receptors by direct protein-protein interactions with the T cell factor family of transcription factors.

El-Tanani M, Fernig DG, Barraclough R, Green C, Rudland P.

J Biol Chem. 2001 Nov 9;276(45):41675-82. Epub 2001 Aug 24.

Supplemental Content

Loading ...
Support Center